ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Gramm-Rudman Cut Facing NCI Could Take $85 Million

October 20, 1989

Health Groups Urge FDA To Regulate Tobacco Products, Including E-Cigarettes

September 5, 2014

DCT Board Agrees To Use Of Program Announcement For New Surgery Grants

March 13, 1981

Two Groups Form to Mark Cancer Act’s 25th Anniversary

May 31, 1996

On Capitol Hill: Cancer Organizations Push Congress For Payment Of Patient Care Costs In Trials

September 17, 1999

DCBDC Board Ok’s New Initiative For Training

November 16, 1990